[HTML][HTML] Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation
BY Owusu, S Thomas, P Venukadasula, Z Han… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Oncotarget, 2017•ncbi.nlm.nih.gov
Targeted therapeutic agents, such as inhibitors of epithelial growth factor receptor (EGFR),
have transformed the management of non-small cell lung cancer (NSCLC) patients. MET-
amplified NSCLC cells display resistance to EGFR-targeting agents, but are addicted to MET
signaling for survival and proliferation and are sensitive to MET inhibition. However,
responsive cancer cells invariably develop resistance to MET-targeted treatment.
have transformed the management of non-small cell lung cancer (NSCLC) patients. MET-
amplified NSCLC cells display resistance to EGFR-targeting agents, but are addicted to MET
signaling for survival and proliferation and are sensitive to MET inhibition. However,
responsive cancer cells invariably develop resistance to MET-targeted treatment.
Abstract
Targeted therapeutic agents, such as inhibitors of epithelial growth factor receptor (EGFR), have transformed the management of non-small cell lung cancer (NSCLC) patients. MET-amplified NSCLC cells display resistance to EGFR-targeting agents, but are addicted to MET signaling for survival and proliferation and are sensitive to MET inhibition. However, responsive cancer cells invariably develop resistance to MET-targeted treatment.
ncbi.nlm.nih.gov
